For instance, all four panels target genes for MPN, but PMP includes MPL exons 3, 4, 5 and 12 recently described as mutated in triple negative patients [78], whereas TSMP, SureSeqTM CoreMPN and MYS panels did not include those exons in their design. This evidence concerns the gene MPL and myeloproliferative disorder.